Introduction
Microtubules (MTs) are integral components of cell structure and function. MT assembly and disassembly are intimately associated with cell proliferation, motility, intracellular transport and differentiation (Andersen, 1999; Downing, 2000; Walczak, 2000) . A unique characteristic of this cytoskeletal component, known as dynamic instability, involves rapid transition between soluble a-and b-tubulin heterodimers and MTs, and is associated with the levels of a number of MT/tubulininteractive proteins (McNally, 1996; Lawler, 1998; Andersen, 2000; Walczak, 2000) .
A recently identified tubulin-binding, cytosolic protein is stathmin (also known as oncoprotein 18 (Op18), p17, p18, p19, 19K, prosolin and metablastin), which acts as a potent regulator of MT stability (Horwitz et al., 1997; Gavet et al., 1998; Larsson et al., 1999; Wallon et al., 2000) . Stathmin sequesters soluble tubulin dimers and stimulates depolymerization at MT plus ends. These two functions appear to reside in different regions of the protein (Howell et al., 1999) . This MT-regulatory function of stathmin is governed by phosphorylation of four of its serine residues, residues 16, 25, 38 and 63. Present data suggest that phosphorylation of two or more of these residues on stathmin halts its MTdestabilizing activity (Moreno and Avila, 1998; Wallon et al., 2000) . Multisite phosphorylation of stathmin by distinct protein kinases is considered essential for the G2/M cell cycle transition (Larsson et al., 1995) .
While control of MT structure appears to be the primary biological task of stathmin, recent reports suggest it to have significant roles in various biological functions. A gradient of active stathmin levels is necessary, since a balance of MT stabilizing and destabilizing factors are essential for maintenance of cellular functions. Stathmin has been found to be overexpressed in highly proliferative breast cancers and in ovarian cancers, particularly those that are platinum drug-resistant (Bieche et al., 1998; Brattsand, 2000; Curmi et al., 2000; Johnsson et al., 2000; Price et al., 2000) . Overexpression of stathmin is also associated with the sensitivity to MT-binding anticancer agents (Alli et al., 2002) . Poorly differentiated prostate tumor epithelial cells express more stathmin than do differentiated cells (Friedrich et al., 1995) . Differentiation-stage-dependent expression of stathmin has also been noted in ovarian cancer (Price et al., 2000) .
Other studies show that stathmin functions as a primary factor in various biological contexts including human disease and development of the nervous system (Friedrich et al., 1995; Johnson et al., 1995; Di Paolo et al., 1996; Lewis et al., 2000; Cheon et al., 2001; Liedtke et al., 2002) . Present models show stathmin expression to be regulated by p53 or p21 WAF1 (Johnsen et al., 2000) . Induction of p53 generally upregulates p21 WAF1/Cip1 and reduces the expression of stathmin; in such a case, p21 WAF1/Cip1 acts as the transcriptional regulator Steinman et al., 2000; Johnsen et al., 2000) . External signals and growth factors like TNFa-, NGF-and EGF-dependent protein kinases are known to lead to stathmin phosphorylation and the associated alterations in MT function, cell cycle, apoptosis and differentiation in various biological systems (Ji et al., 1993; Di Paolo et al., 1996 , Vancompernolle et al., 2000 Hummert et al., 2000) . Induced expression of the catalytic subunit of cAMPdependent protein kinase A also results in increased cellular MT polymer content, phosphorylation and partial degradation of stathmin in K562 cells (Gradin et al., 1998) . Selective depletion of stathmin prevents the differentiation-promoting actions of NGF in PC 12 cells; in the absence of stathmin, these cells are unable to respond to NGF (Di Paolo et al., 1996) . Studies in vitro have shown that antisense RNA inhibition of stathmin abrogates the transformed phenotype of K562 leukemia cells (Iancu et al., 2000) . Stathmin production and expression is high in immature chondrocytes as compared to the growth zone chondrocytes (Hummert et al., 2000) . In consideration of the significant role of stathmin, primarily its association with MT function, cell cycle, differentiation and altered expression in various cancers, elucidation of the nature of its regulatory controls will be useful to discern a variety of cellular signal transduction pathways.
In the present work, we determined that two Ptxresistant ovarian cancer cell lines, 1A9/Ptx-10 and 1A9/ Ptx-22, have elevated expression levels of stathmin. These lines were isolated from the 1A9 cell line, a clone from the A2780 cell line, by continuous exposure to Ptx and verapamil (the latter to avoid expression of multidrug resistance mediated by the transporter encoded by ABC1, also known as MDR1, the P-glycoprotein pump). The two Ptx-resistant lines have point mutations in the major b-tubulin gene, M40 (1A9/Ptx-10: codon 270, Phe-Val; 1A9/Ptx-22: codon 364, Ala-Thr) as well as point mutations in one or both alleles of the TP53 gene (1A9/Ptx-10: codon 236, Tyr-Cys in one allele leading to a dominant-negative p53 phenotype; 1A9/Ptx-22: codon 239, Asn-Asp in both alleles) (Giannakakou et al., 2000) . Previous work has also shown these resistant lines to express lower levels of Bax (Poruchynsky et al., 2001) . In this study, the expression of stathmin in these cells was found to be independent of p53/p21 WAF1/Cip1 regulation. Our results show that MT-stabilizing drug resistance in ovarian carcinoma may be associated with altered p53/21 WAF1/Cip1 regulatory pathways for stathmin expression.
Results

Growth rate and stathmin
1A9/Ptx-10 and 1A9/Ptx-22 cells are maintained in culture medium containing 15 ng/ml Ptx and 5 mg/ml verapamil, while the parental 1A9 line is passaged in the absence of these drugs. In preliminary experiments, the three cell lines were grown in the absence of Ptx/verapamil and tested daily for 4 days by cell counting (Figure 1 ) and Western blots using rabbit antistathmin antibody to identify any correlations between growth rates and changes in stathmin levels. Stathmin was detected in lysates of all three cell lines. Densitometric analysis of Western blots indicated that the two Ptx-resistant cell lines had two-to threefold higher levels of stathmin as compared to the parental cell line (Figure 2 ). Subsequently, cells were plated and allowed to attach and grow for 24 h, then treated with 15 ng/ml Ptx for an additional 24 h. Ptx reduced the survival of 1A9 cells considerably but, as expected, had no effect on the proliferation of resistant cells; yet, the stathmin levels did not change substantially in any of the three cell lines as a result of Ptx treatment (Figure 2 ).
Cell cycle regulators
New Western blots prepared from lysates of Ptx-treated and -untreated cells from the same experiment were then probed, or the original stathmin filters were reprobed, for p21 WAF1/Cip1 . While the 1A9 cell line expressed a very low basal level of p21
, Ptx-treated 1A9 cells showed a dramatic increase in the levels of this protein, approximately 150-fold ( Figure 2 ). However, this increase in p21 WAF1/Cip1 had no substantial influence on stathmin levels in 1A9 cells. Neither 1A9/Ptx-10 nor 1A9/ Ptx-22 cells had detectable basal levels of p21
. This is likely a function of the point mutations in TP53 in these cells (Giannakakou et al., 2000) .
Western blotting with a pan-anti-p53 antibody showed that the 1A9 cell line had undetectable or very low basal levels of wild-type p53 protein, while resistant cells expressed several-fold higher levels of their respective mutant p53 proteins. Treatment of 1A9 with Ptx cells caused an increase in p53, but the level of wildtype p53 in the 1A9 cells, even after the Ptx-induced The status of MDM2, a negative regulator of p53, was also examined in the three cell lines. 1A9 cells expressed a very low basal level of MDM2. Ptx increased MDM2 expression, resulting in multiple forms immunodetected as discrete bands (Jimenez et al., 1999) . In the Ptx-resistant cell lines, basal MDM2 levels were either very low or only lower molecular weight forms of the protein were detected (Figure 2 ). In general, Ptx increased the expression of p21
, p53 and MDM2 several-fold in 1A9 cells, whereas the Ptx-resistant cells did not express detectable levels of these proteins or the levels remain unchanged upon Ptx treatment. Cells from the three lines, whether drug treated or not, showed no major changes in the levels of proliferative cell nuclear antigen (PCNA), tyrosine-phosphorylated p34
Cdc2 or the a and b isoforms of tubulin ( Figure 2 ).
Loading control proteins
As a loading control, Western blots were also reprobed for the levels of b-actin. Unlike the parental 1A9 cell line, the Ptx-resistant cells contained 50-70% less b-actin per unit total protein ( Figure 2 ). Therefore, for quantitation of protein bands and as an internal control, the blots were reprobed for the presence of the endoplasmic reticulum protein calreticulin (Michalak et al., 1999) . Calreticulin proved to be a reliable internal control since its stable expression is an indication of the structural and functional integrity of the cell. The levels of this 60 kDa protein remained unchanged in Ptxtreated and -untreated cells (Figure 2 ).
Cell cycle alterations
Flow cytometry using propidium iodide to quantify the population distribution of cellular DNA content showed that Ptx treatment altered 1A9 cell cycle, causing G2/M arrest and the appearance of hypodiploid cells (Figure 4 ). Flow histograms of Ptx-treated resistant cells were similar to those of DMSO-treated controls. Presumably, Ptx could not bind the mutated b-tubulin of the resistant cells and therefore was unable to stabilize the MTs within them and lead to the G2/M arrest the drug typically causes (Giannakakou et al., 1997) .
Infection with a P53-producing adenovirus
In the next series of experiments, Ptx-resistant cells were treated with an adenovirus bearing wild-type TP53 under the control of a constitutive promoter (Katayose et al., 1995) . The adenovirus negative control, d1312, was the same virus containing the same promoter but lacked the wild-typeTP53. Virus load was titered to give multiplicity of infection (MOI) levels of 5 and 10. At 24 h after treatment with AdWTp53, cell lysates were subjected to Western blot analysis for stathmin and p21 WAF1/Cip1 . Aliquots of the cells from this experiment were also analysed by flow cytometry. In the Western blots, an equal amount of protein from a lysate of the parental 1A9 cell line was also included for comparison. The goal was to determine if the introduced wild-type p53 or the expected increase in p21 WAF1/Cip1 would act as transcriptional repressors in the drug-resistant cells to block stathmin expression and reduce its abundance to the low level found in the parental cell line. Infection using the wild-type TP53 in the mutant p53-expressing 1A9/Ptx-10 and 1A9/Ptx-22 cells did indeed cause several-fold increases in cellular p21
, but no major changes were noted in the stathmin levels ( Figure 5 ). These findings indicated that neither p53 nor p21 WAF1/Cip1 acted as a downregulator, or as an inhibitor, necessary to block the expression of stathmin. Treatment with the d1312 control virus that lacked TP53 caused no changes in p21 WAF1/Cip1 levels in 1A9/Ptx-10 and 1A9/Ptx-22 cell lines. Treatment of the parental cell line with AdWTp53 caused, however, a 25% decrease in stathmin levels (data not shown).
AdWTp53-infected cells were also examined for MDM2.1A9/Ptx-10, and 1A9/Ptx-22 cells showed abundant expression of MDM2, indicating that the p53 regulatory pathway was fully reconstituted ( Figure 5 ). Examination for Bcl2 indicated that this antiapoptotic protein showed a correlation to stathmin, with a low-to-undetectable level in parental cells but 20-40-fold levels in the two resistant cells. AdWTp53 treatment did not alter the level of Bcl2, nor did it substantially modify the levels of b-actin, PCNA, calreticulin or tyrosine-phosphorylated p34 Cdc2 ( Figure 5 ). It was also anticipated that the increased p21 WAF1/Cip1 would lower the level of tyrosine-phosphorylated p34
Cdc2 (Gu et al., 1993) , but this did not occur. AdWTp53 treatment apparently changed the cell cycle distribution in both resistant cell lines, including the appearance of a hypodiploid population (Figure 6 ). In comparison to the d1312-infected cells, 1A9/Ptx-10 cells treated with AdWTp53 had 10% of the fluorescent events in the hypodiploid portion of the histogram and a 40% reduction in the population of G1 cells, whereas in 1A9/Ptx-22 cells 26-56% of fluorescent events were in the hypodiploid region and the reduction in G1 phase cells ranged from 54 to 70% (with 5-10 MOI). The duration of AdWTp53 exposure (24 h) was longer than the doubling times of the two drug-resistant cell lines. Presumably, the increased expression of wild-type p53 and resulting upregulation of p21 WAF1/Cip1 levels blocked the cells from traversing G1 through S phases, or the G2/M boundary, whereupon the cells apoptosed. Treatment with the negative control virus to give an MOI of 10 did not lead to any change in the cell cycle distribution. These findings are in general agreement with the fact that the major changes in cell cycle distribution resulted in reduced cell proliferation and formation of a hypodiploid population after wild-type p53 expression.
Soluble vs polymerized tubulin
Although the preliminary experiments indicated a correlation of stathmin with cell proliferation and drug resistance, a functional relationship for MT dynamics in The ratio of polymerized to soluble tubulin is an indication of stathmin function. In order to identify a correlation between polymerized/soluble tubulin and overexpression of stathmin, the resistant cell lines were treated with Ptx þ verapamil or with vehicle only, and the tubulin fractions were separated from cell lysates by centrifugation (Giannakakou et al., 1997) . Western blot analysis for a-and b-tubulin showed most of the protein to be in the soluble form; however, a 3-10-fold increased level of polymerized tubulin was detected in the Ptxresistant cell lines (Figure 7) . Therefore, even though there was excess stathmin in the resistant cells, more stable tubulin polymers were formed, suggesting that the extra stathmin in the drug-resistant cells was in its phosphorylated form and could not destabilize MTs. Ptx treatment did not change the ratio of soluble to polymerized tubulin.
As the cellular fraction with the polymerized tubulin also contained nuclei, the filters from electrophoretic analysis for polymerized/soluble tubulin were reprobed for tyrosine-phosphorylated p34
Cdc2
. The drug-resistant cells contained 20-30-fold more of this protein in the nuclear fraction (Figure 7) . The presence of phosphoTyr p34 Cdc2 in the nucleus is an indication of frequent nuclear envelope breakdown, as the cells are undergoing a higher rate of mitosis compared to the slow growing parental cell line (McNally, 1996) .
Discussion
Cells undergo a number of changes at the molecular level during transformation from normal/benign form to neoplastic to drug-resistant, aggressive tumors. Generally, such changes occur in oncogenes or in the genes coding regulators of cell cycle and signal transduction cascades. Interestingly, even though Ptx resistance in the 1A9/Ptx-10 and 1A9/Ptx-22 cells is primarily associated with point mutations in their major b-tubulin gene, point mutations also exist in one or both TP53 alleles of these cells. Although the tubulin expression levels in these cells remained essentially unchanged, mutant p53 protein was expressed at levels much higher in the Ptx-resistant lines than was the wildtype p53 found in the parental line (also noted in Giannakakou et al., 1997 Giannakakou et al., , 2000 . One key protein, stathmin, a tubulin-binding protein that destabilizes MTs, has been found to be overexpressed in ovarian cancer (Price et al., 2000) . Screening of the parental 1A9 and Ptx-resistant 1A9/Ptx-10 and 1A9/Ptx-22 ovarian cancer cell lines by Western blotting indicated that the drug-resistant cell lines had increased levels of stathmin. Stathmin expression as detected by Western blotting correlated with the proliferation rates of the cell lines. The parental cell line with low stathmin levels had a slower growth rate as compared to the resistant cell lines (Figure 1 ). This is in contrast with studies that show overexpression of stathmin results in inhibition rather than increases in cell growth (Marklund et al. 1994) . On the other hand, this correlation between growth rate and stathmin levels is in agreement with one known function of stathmin, disassembly of spindle MTs and exit from mitosis; that is, a cell with an increased polymerized state of tubulin presumably would require more stathmin to help in MT spindle dynamics than would a cell with a lower state of polymerized tubulin. Generally, overexpression of stathmin is considered a feature of proliferating cells . In cells with normal tubulin, stathmin expression levels are correlated with Ptx sensitivity (Iancu et al., 2000) . Apparently, overexpressed stathmin is an advantage to the Ptx-resistant cells, enabling them to divide at a faster rate, a general characteristic of the highly proliferative tumor cells. This is also an indication of the changed MT dynamics of these cells.
The resistant cell lines did not express p21 WAF1/Cip1 and had shorter doubling times. P53/p21 WAF1/Cip1 has been reported to be the transcriptional regulator of stathmin, with a consensus sequence in the promoter of the stathmin gene Johnsen et al., 2000; Steinman et al., 2000) . In the Ptx-resistant cells, p21 WAF1/Cip1 was absent, indicating that the mutant p53 could not act as a transcriptional activator. The placement of wild-type p53 into these cells by viral infection restored the p53 pathway as evidenced by the expression of p21 WAF1/Cip1 , MDM2 and changes in cell cycle distribution. Wild-type p53 transcriptionally activated p21 WAF1/Cip1 . Such an increase in p21 WAF1/Cip1 expression was expected to result in the downregulation of stathmin. Yet, the wild-type p53-mediated increase in p21 WAF1/Cip1 expression in the two Ptx-resistant cell lines did not lower the stathmin levels to that seen in parental cells. Another significant observation in the parental 1A9 cells was that Ptx increased the expression of p21 WAF1/Cip1 , changed the cell cycle distribution and caused the majority of the cells to lose DNA and enter hypodiploid status. Yet, none of these changes substantially altered the basal level expression of stathmin. Subsequently, other proteins directly associated with DNA replication and cell cycle were examined to identify their role in stathmin overexpression. Neither PCNA nor tyrosine-phosphorylated p34 Cdc2 levels differed between the resistant and sensitive cell lines in the absence or presence of wild-type p53, but the resistant cell Cdc2 in vehicle-treated 1A9 and paclitaxel (15 ng/ml)-or vehicle-treated 1A9/Ptx-10 and 1A9/Ptx-22 cells. 1A9 (lanes 1, 4, 7 and 10); 1A9/Ptx-10 (lanes (2, 5, 8 and 11); 6, 9 and 12) . Lanes 8, 9, 11 and 12 represent lysates from paclitaxel-treated cells, lanes 1-3 and 7-9, microtubule-containing pellet and lanes 4-6 and 10-12, soluble cell fraction Johnsen et al., 2000; Steinman et al., 2000) . In those studies, stathmin mRNA was used as a metric of effect. Transcriptional regulation by p53 depends on other factors. For example, wild-type p53 regulation of MAP-4 and stathmin depends on histone deacetylases in association with mSin3a . Others and we have seen that the Ptxresistant cells have multiple changes like mutations in the genes encoding p53 and b-tubulin, as well as reduced expression of actin and Bax and increased Bcl2. In the light of the current data, it appears that an abrogated stathmin-p53/p21 WAF1/Cip1 -regulatory pathway is present in these Ptx-selected cells. Although stathmin is reported to be essential for passage through mitosis, the resistant cells underwent changes in cell cycle distribution when treated with AdWTp53 without concomitant major changes in stathmin levels. On the other hand, stathmin expression was directly correlated with cell proliferation rate in the context of polymerized tubulin in association with levels of tyrosine-phosphorylated p34
Cdc2
. Phosphorylation of p34
Cdc2 is known to play a major role in cell cycle progression, especially in the G2/M phase, and stathmin phosphorylation (leading to increased stability of MTs) is an important function of p34
Cdc2 (Mistry and Atweh, 2001) . When cell lysates were separated into the fractions containing polymerized and soluble tubulins, the resistant cells showed retention of more tyrosinephosphorylated p34
Cdc2 in the MT/nuclear fraction (McNally, 1996) . The increased stathmin level was correlated with the increased polymerized tubulin and tyrosine-phosphorylated p34
Cdc2 in the two resistant cells. Characteristically, the Ptx-resistant cell lines also expressed more of the antiapoptotic protein Bcl2 ( Figure 5 ) and less of the proapoptotic protein Bax (Poruchynsky et al., 2001) , a phenotype that is associated with chemoresistance in aggressive tumors (Reed, 1995) . The sum of these results implicates an important role for stathmin in the Ptx resistance of these cells.
Phosphorylation of stathmin abrogates its MT destabilizing activity, leading to an increased level of MT polymer and stabilized MTs in vivo. It is presently unknown whether all of this 'extra' stathmin observed in Ptx-resistant cells has a cellular target different from MTs. Overall, our results indicate that MT drug resistance in ovarian carcinoma may be associated with altered p53/21 WAF1/Cip1 regulatory pathways for stathmin expression and function.
Materials and methods
Paclitaxel, obtained from the Drug Synthesis Branch of the National Cancer Institute, was dissolved in DMSO as a stock solution. Control samples contained DMSO vehicle at a level (0.1% v/v) equivalent to that in the drug-treated cultures. The 1A9, 1A9/Ptx-10 and 1A9/Ptx-22 cell lines were a generous gift from Drs Tito Fojo and Paraskevi Giannakakou, National Cancer Institute. Cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum at 371C in a humidified, 5% CO 2 incubator. 1A9/Ptx-10 and 1A9/Ptx-22 cells were maintained in the presence of 15 ng/ml Ptx and 5 mg/ml verapamil. This medium was replaced with drug-free, regular medium 3 days before the experiments. Generally, trypsinized cells were plated for 24 h and treated with Ptx or other reagents (e.g., AdWTp53 or adenovirus control d1312) for an additional 24 h. Cell growth was monitored by counting Trypan blue-excluding cells microscopically with the aid of a hemacytometer. Antibodies were obtained from the following vendors: rabbit anti-stathmin, mouse anti-p21 WAF1/Cip1 and -MDM2 from Calbiochem; mouse anti-p53, -PCNA and -p34
Cdc2 from Santa Cruz Biotechnologies; mouse anti-tubulins from Lab Vision; rabbit polyclonal anti-calreticulin from Affinity Bioreagents; anti-phosphoTyr15 p34
Cdc2 from New England Biolabs; mouse anti-Bcl-2 from Dako; and rabbit anti-b-actin from Sigma. AdWTp53 and control d1312 viruses were generous gifts from Dr Shiv Srivastava, CPDR, USUHS, Rockville, MD, USA.
Western blotting
Cells were washed three times in cold Hank's balanced salts solution (HBSS) and lysed in 50 mM Tris-HCl buffer, pH 7.4, containing 1% NP-40, 150 mM NaCl, 0.25% w/v sodium deoxycholate, 1 mM EDTA and Completet protease inhibitor cocktail (Boehringer, Mannheim). After centrifugation at 41C, the supernatant was diluted 1 : 100 and protein was estimated using the Biorad DC protein assay. Equal amounts of protein were loaded into wells of 12% polyacrylamide gels and separated by electrophoresis. Proteins were transferred to PVDF (Biorad) membranes using a Biorad Trans-Blot SemiDry transfer system. Membranes were washed in 50 mM Tris buffer, pH 7.4, containing 0.5 M NaCl, 0.1% v/v Tween 20, and then blocked using the Amersham-provided agent. The Amersham ECL chemiluminescence system and Fuji film were used to detect the protein bands. Films were scanned and protein bands were quantified with a Biorad MultiFluor-S and Multi-Analyst/PC s Image Analysis system.
Cell cycle analysis
Cellular DNA content was quantified by flow cytometric determination of propidium iodide intercalated into DNA of intact, fixed cells. Trypsinized cells were washed three times using cold HBSS and fixed in 70% ethanol at À201C for 1 h or overnight. Cells were then washed with cold HBSS, treated with RNAseA (100 mg/ml) and propidium iodide and the cells were stored in the dark at 41C overnight. DNA content was determined using a Becton-Dickinson FACScan flow cytometer equipped with a 488 nm Ar laser by measuring forward and orthogonal light scatter and peak and area red fluorescence. Cell cycle populations were quantified from a standard count of 10 000 cells using the Lysis II program.
Analysis of cellular levels of polymerized and soluble tubulin and associated proteins
Polymerized and soluble tubulin from cells was prepared as described (Giannakakou et al., 1997) . Briefly, cell lysates were centrifuged at room temperature for 15 min. Equal amounts of protein from the soluble (supernatant) and polymerized (pellet) fractions were subjected to electrophoresis through 12% polyacrylamide gels followed by Western blotting as described above.
Abbreviations HBSS, Hank's balanced salts solution; MOI, multiplicity of infection; MT, microtubule; PCNA, proliferative cell nuclear antigen; Ptx, paclitaxel.
